The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials

Visual Abstract Significance Statement Reliable prediction tools are needed to personalize treatment in ANCA-associated GN. More than 1500 patients were collated in an international longitudinal study to revise the ANCA kidney risk score. The score showed satisfactory performance, mimicking the original study (Harrell's C=0.779). In the development cohort of 959 patients, no additional parameters aiding the tool were detected, but replacing the GFR with creatinine identified an additional cutoff. The parameter interstitial fibrosis and tubular atrophy was modified to allow wider access, risk points were reweighted, and a fourth risk group was created, improving predictive ability (C=0.831). In the validation, the new model performed similarly well with excellent calibration and discrimination (n=480, C=0.821). The revised score optimizes prognostication for clinical practice and trials. Background Reliable prediction tools are needed to personalize treatment in ANCA-associated GN. A retrospective international longitudinal cohort was collated to revise the ANCA renal risk score. Methods The primary end point was ESKD with patients censored at last follow-up. Cox proportional hazards were used to reweight risk factors. Kaplan–Meier curves, Harrell's C statistic, receiver operating characteristics, and calibration plots were used to assess model performance. Results Of 1591 patients, 1439 were included in the final analyses, 2:1 randomly allocated per center to development and validation cohorts (52% male, median age 64 years). In the development cohort (n=959), the ANCA renal risk score was validated and calibrated, and parameters were reinvestigated modifying interstitial fibrosis and tubular atrophy allowing semiquantitative reporting. An additional cutoff for kidney function (K) was identified, and serum creatinine replaced GFR (K0: <250 µmol/L=0, K1: 250–450 µmol/L=4, K2: >450 µmol/L=11 points). The risk points for the percentage of normal glomeruli (N) and interstitial fibrosis and tubular atrophy (T) were reweighted (N0: >25%=0, N1: 10%–25%=4, N2: <10%=7, T0: none/mild or <25%=0, T1: ≥ mild-moderate or ≥25%=3 points), and four risk groups created: low (0–4 points), moderate (5–11), high (12–18), and very high (21). Discrimination was C=0.831, and the 3-year kidney survival was 96%, 79%, 54%, and 19%, respectively. The revised score performed similarly well in the validation cohort with excellent calibration and discrimination (n=480, C=0.821). Conclusions The updated score optimizes clinicopathologic prognostication for clinical practice and trials.

[1]  S. Bell,et al.  Outcomes in ANCA-Associated Vasculitis in Scotland: Validation of the Renal Risk Score in a Complete National Cohort , 2023, Kidney international reports.

[2]  M. van Smeden,et al.  Developing, validating, updating and judging the impact of prognostic models for respiratory diseases , 2022, European Respiratory Journal.

[3]  N. Takahashi,et al.  Evaluation of a newly proposed renal risk score for Japanese patients with ANCA-associated glomerulonephritis , 2022, Clinical and Experimental Nephrology.

[4]  G. Collins,et al.  Methodological conduct of prognostic prediction models developed using machine learning in oncology: a systematic review , 2022, BMC Medical Research Methodology.

[5]  M. Copin,et al.  Assessment of Renal Risk Score and Histopathological Classification for Prediction of End-Stage Kidney Disease and Factors Associated With Change in eGFR After ANCA-Glomerulonephritis Diagnosis , 2022, Frontiers in Immunology.

[6]  T. Therneau,et al.  Assessing performance and clinical usefulness in prediction models with survival outcomes: practical guidance for Cox proportional hazards models , 2022, medRxiv.

[7]  J. Aniort,et al.  Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges , 2022, Journal of the American Society of Nephrology : JASN.

[8]  Jie Feng,et al.  Meta-Analytical Accuracy of ANCA Renal Risk Score for Prediction of Renal Outcome in Patients With ANCA-Associated Glomerulonephritis , 2022, Frontiers in Medicine.

[9]  U. Specks,et al.  Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  P. Luo,et al.  Validation of the renal risk score for antineutrophil cytoplasmic antibody-associated glomerulonephritis in a Chinese population , 2021, Clinical Rheumatology.

[11]  G. Canaud,et al.  Reappraisal of Renal Arteritis in ANCA-associated Vasculitis: Clinical Characteristics, Pathology, and Outcome , 2021, Journal of the American Society of Nephrology : JASN.

[12]  A. Rosenberg,et al.  Application of the ANCA Renal Risk Score in the United States: A Single-Center Experience , 2021, Kidney medicine.

[13]  K. Moon,et al.  Histopathologic and clinicopathologic classifications of antineutrophil cytoplasmic antibody-associated glomerulonephritis: a validation study in a Korean cohort , 2021, Kidney research and clinical practice.

[14]  C. Pusey,et al.  Validation of the ANCA renal risk score in a London cohort: potential impact of treatment on prediction outcome. , 2021, Kidney international.

[15]  N. Chen,et al.  Evaluating renal outcome of ANCA-associated renal vasculitis: comparative study of two histopathological scoring systems. , 2020, Clinical and experimental rheumatology.

[16]  Qiongxiu Zhou,et al.  Predictors of renal outcomes in crescentic and mixed class of ANCA-associated glomerulonephritis. , 2020, Clinical nephrology.

[17]  C. Zeng,et al.  Consensus Definitions for Glomerular Lesions by Light and Electron Microscopy: Recommendations from a Working Group of the Renal Pathology Society. , 2020, Kidney international.

[18]  T. Cavero,et al.  Long-term validation of the renal risk score for vasculitis in a Southern European population , 2020, Clinical kidney journal.

[19]  Richard D Riley,et al.  Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal , 2020, BMJ.

[20]  D. Solmaz,et al.  Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis , 2020, Annals of the Rheumatic Diseases.

[21]  J. Mejía-Vilet,et al.  Validation of a renal risk score in a cohort of ANCA-associated vasculitis patients with severe kidney damage , 2020, Clinical Rheumatology.

[22]  M. Zouaghi,et al.  Predictors of renal outcomes in anti-neutrophil cytoplasmic antibody glomerulonephritis , 2020, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[23]  Maarten van Smeden,et al.  Calibration: the Achilles heel of predictive analytics , 2019, BMC Medicine.

[24]  R. Wolterbeek,et al.  A renal risk score for ANCA-associated glomerulonephritis. , 2019, Kidney international.

[25]  H. Denley,et al.  ANCA renal risk score predicts outcome in the Manchester cohort. , 2019, Kidney international.

[26]  D. Pinder.  Limburg , 2019, The Netherlands.

[27]  Chava L. Ramspek,et al.  Towards the best kidney failure prediction tool: a systematic review and selection aid , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  U. Panzer,et al.  Development and validation of a renal risk score in ANCA-associated glomerulonephritis. , 2018, Kidney international.

[29]  Jai Radhakrishnan,et al.  A proposal for standardized grading of chronic changes in native kidney biopsy specimens. , 2017, Kidney international.

[30]  N. Chen,et al.  Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis , 2017, The Journal of Rheumatology.

[31]  L. Bostad,et al.  Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[32]  J. Levy,et al.  Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  S. Stancu,et al.  ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study , 2015, BMC Nephrology.

[34]  S. Quaglini,et al.  Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature. , 2015, Clinical and experimental rheumatology.

[35]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[36]  G. Collins,et al.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement , 2015, BMC Medicine.

[37]  V. Derebail,et al.  Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[38]  Jean-François Dartigues,et al.  Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risks , 2013, Statistics in medicine.

[39]  P. Royston,et al.  External validation of a Cox prognostic model: principles and methods , 2013, BMC Medical Research Methodology.

[40]  Min Chen,et al.  Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[42]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[43]  R. Wolterbeek,et al.  Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. , 2006, Journal of the American Society of Nephrology : JASN.

[44]  H. V. van Houwelingen,et al.  An index for renal outcome in ANCA-associated glomerulonephritis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  H. V. van Houwelingen,et al.  Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. , 2002, Kidney international.

[46]  J. Stone,et al.  Correlation of Percentage of Normal Glomeruli with Renal Outcome in Wegener’s Granulomatosis , 2002, American Journal of Nephrology.

[47]  L. Bostad,et al.  Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  J. Hermans,et al.  Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. , 1999, Kidney international.

[49]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[50]  Mariana Solinho,et al.  Involvement , 2019, Moscow's Third World Strategy.

[51]  A. Soleiman,et al.  Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  J. Ioannidis,et al.  Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  H C van Houwelingen,et al.  Validation, calibration, revision and combination of prognostic survival models. , 2000, Statistics in medicine.